ARVINAS, INC. — Regulatory Filings 2025

Feb 11, 2025

S-8 1 arvn-evergreensx8february1.htm S-8 Document created using Wdesk Copyright 2025 Workiva Document

As filed with the Securities and Exchange Commission on February 11, 2025

Registration No. 333-

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

---

FORM S-8

REGISTRATION STATEMENT

UNDER

THE SECURITIES ACT OF 1933

---

ARVINAS, INC.

(Exact Name of Registrant as Specified in Its Charter)

---

Delaware	47-2566120
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
5 Science Park 395 Winchester Ave. New Haven, Connecticut	06511
(Address of Principal Executive Offices)	(Zip Code)

2018 Stock Incentive Plan

2018 Employee Stock Purchase Plan

(Full Title of the Plans)

John Houston, Ph.D.

President and Chief Executive Officer

Arvinas, Inc.

5 Science Park

395 Winchester Ave.

New Haven, Connecticut 06511

(Name and Address of Agent for Service)

(203) 535-1456

(Telephone Number, Including Area Code, of Agent for Service)

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
		Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

EXPLANATORY NOTE

This Registration Statement on Form S-8, relating to the 2018 Stock Incentive Plan and the 2018 Employee Stock Purchase Plan of Arvinas, Inc. (the “Registrant”), is being filed for the purpose of registering additional securities of the same class as other securities for which a Registration Statement on Form S-8 has previously been filed and is effective. Accordingly, this Registration Statement incorporates by reference the contents of (i) the Registration Statement on Form S-8, File No. 333-227555 , filed with the Securities and Exchange Commission (the “SEC”) on September 27, 2018 by the Registrant, relating to the Registrant’s Incentive Share Plan, as amended, 2018 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, (ii) the Registration Statement on Form S-8, File No. 333-231388 , filed with the SEC on May 10, 2019 by the Registrant, relating to the Registrant’s 2018 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, (iii) the Registration Statement on Form S-8, File No. 333-237215 , filed with the SEC on March 16, 2020 by the Registrant, relating to the Registrant’s 2018 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, (iv) the Registration Statement on Form S-8, File No. 333-253721 , filed with the SEC on March 1, 2021 by the Registrant, relating to the Registrant’s 2018 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, (v) the Registration Statement on Form S-8, File No. 333-263095 , filed with the SEC on February 28, 2022 by the Registrant, relating to the Registrant’s 2018 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, (vi) the Registration Statement on Form S-8, File No. 333-270010 , filed with the SEC on February 24, 2023 by the Registrant, relating to the Registrant’s 2018 Stock Incentive Plan and 2018 Employee Stock Purchase Plan, and (vii) the Registration Statement on Form S-8, File No. 333-276519 , filed with the SEC on January 16, 2024 by the Registrant, relating to the Registrant’s 2018 Stock Incentive Plan, 2018 Employee Stock Purchase Plan, Inducement Stock Option Award (January 2024) and Inducement Restricted Stock United Award (January 2024), in each case, except to the extent amended or superseded by the contents hereof.

Item 8. Exhibits

The following exhibits are incorporated herein by reference:

Exhibit No.	Description
4.1(1)	Restated Certificate of Incorporation of the Registrant
4.2(2)	Second Amended and Restated Bylaws of the Registrant
5.1 *	Opinion of Wilmer Cutler Pickering Hale and Dorr LLP, counsel to the Registrant
23.1 *	Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1)
23.2 *	Consent of Deloitte & Touche LLP, independent registered public accounting firm for the Registrant
24.1 *	Power of Attorney (included on the signature pages of this registration statement)
99.1(3)	2018 Stock Incentive Plan
99.2(4)	2018 Employee Stock Purchase Plan
FILING FEES *	Calculation of Filing Fee Tables

(1)	Previously filed with the Securities and Exchange Commission on October 1, 2018 as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) and incorporated herein by reference.
(2)	Previously filed with the Securities and Exchange Commission on June 21, 2023 as Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) and incorporated herein by reference.
(3)	Previously filed with the Securities and Exchange Commission on September 14, 2018 as Exhibit 10.4 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-227112) and incorporated herein by reference.
(4)	Previously filed with the Securities and Exchange Commission on September 14, 2018 as Exhibit 10.6 to the Registrant’s Registration Statement on Form S-1/A (File No. 333-227112) and incorporated herein by reference.
*	Filed herewith

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New Haven, State of Connecticut, on this 11th day of February, 2025.

ARVINAS, INC.
By:	/s/ John Houston, Ph.D.
	John Houston, Ph.D.
	President and Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

We, the undersigned officers and directors of Arvinas, Inc., hereby severally constitute and appoint John Houston, Ph.D. and Andrew Saik, and each of them singly, our true and lawful attorneys with full power to any of them, and to each of them singly, to sign for us and in our names in the capacities indicated below the Registration Statement on Form S-8 filed herewith and any and all amendments to said Registration Statement, and generally to do all such things in our names and on our behalf in our capacities as officers and directors to enable Arvinas, Inc. to comply with the provisions of the Securities Act of 1933, as amended, and all requirements of the Securities and Exchange Commission, hereby ratifying and confirming our signatures as they may be signed by our said attorneys, or any of them, to said registration statement and any and all amendments thereto.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

Signature	Title	Date
/s/ John Houston, Ph.D.	President, Chief Executive Officer and Chairman of the Board of Directors (principal executive officer)	February 11, 2025
John Houston, Ph.D.
/s/ Andrew Saik	Chief Financial Officer and Treasurer (principal financial officer)	February 11, 2025
Andrew Saik
/s/ David K.Loomis	Vice President and Chief Accounting Officer (principal accounting officer)	February 11, 2025
David K. Loomis
/s/ Sunil Agarwal, M.D.	Director	February 11, 2025
Sunil Agarwal, M.D.
/s/ Linda Bain	Director	February 11, 2025
Linda Bain
/s/ Everett Cunningham	Director	February 11, 2025
Everett Cunningham
/s/ Edward Kennedy, Jr.	Director	February 11, 2025
Edward Kennedy, Jr.
/s/ Briggs Morrison, M.D.	Director	February 11, 2025
Briggs Morrison, M.D.
/s/ Leslie Norwalk, Esq.	Director	February 11, 2025
Leslie Norwalk, Esq.
/s/ Laurie Smaldone Alsup, M.D.	Director	February 11, 2025
Laurie Smaldone Alsup, M.D.
/s/ John Young	Director	February 11, 2025
John Young